June 2003 By Rob Camp To lipid it or not to lipid it From the Introduction Atazanavir (ATV) is an azapeptide protease inhibitor under development by Bristol- Myers Squibb, licensed from Novartis. Overall, the drug looks virologically similar to nelfinavir…
TAG Basic Science Project 2003 Retrovirus Conference Report By Richard Jeffreys May 2003 Nabbing the V3 Loop One major theme that emerged at this year's Retrovirus conference was a renaissance of interest in neutralizing antibodies. Antibodies are small Y-shaped molecules…
2003 by Rob Camp INTRODUCTION FTC is a once-daily (QD) thiacytidine nucleoside analogue developed by Triangle Pharmaceuticals, North Carolina. Triangle is now owned by Gilead Sciences. The compound was licensed from Emory University in 1996. It comes in 200 mg…
By Matt Sharp and Rob Camp for the Treatment Action Group (TAG) and Other Endorsing Community Organizations and Individuals (List Below) March 7, 2003 Introduction Research and advocacy have brought forth 16 approved antiviral medications targeting two different stages in…
By Richard Jeffreys January/February 2003 IL-2 & CD4 T Cells: Number & Function Disconnect? Therapeutic Dendritic Cell Vaccine Lowers SIV Load Protease Inhibitors and Atherosclerosis Immune Activation & Immune Deficiency: Making the Connection New Insights Into HIV Latency Viral Adaptation…
Research and Policy Recommendations for HCV/HIV Coinfection By Tracy Swan February 2003 Introduction The unfolding epidemic of hepatitis C virus (HCV) infection is a serious and growing problem. An estimated 170 million people around the world are infected. In the…
by Richard Jeffreys January 29, 2003 When an investigational drug causes a 0.4 log drop in viral load, it is evidence of biological activity. When the first large auto-vaccination study produces the same result, it signals the end of an…
This is the first in a series of periodic reviews of the scientific literature that the Basic Science Project will be making available via the TAG website. September 2002 Exploding CD4 T Cell Counts STIs in Chronic Infection: Predicting Success…
by Richard Jeffreys May 2002 Every year, Keystone Symposia sponsor two parallel conferences on HIV pathogenesis and vaccines. The meetings take place at the Keystone Resort high in the Rocky Mountains, allowing researchers to mix the latest data with a…